Details

Autor(en) / Beteiligte

• Ito, Shunsuke
• Ikuno, Tatsuya
• Mishima, Masayuki
• Yano, Mariko
• Hara, Toshiko
• Kuramochi, Taichi
• Sampei, Zenjiro
• Wakabayashi, Tetsuya
• Tabo, Mitsuyasu
• Chiba, Shuichi
• Kubo, Chiyomi

Titel

In vitro human helper T-cell assay to screen antibody drug candidates for immunogenicity

Ist Teil von

• Journal of immunotoxicology, 2019-01, Vol.16 (1), p.125-132

Ort / Verlag

England: Taylor & Francis

Erscheinungsjahr

2019

Quelle

MEDLINE

Beschreibungen/Notizen

• Monoclonal antibody (mAb) drugs offer a number of valuable treatments. Many newly developed mAb drugs include artificial modification of amino acid sequences from human origin, which may cause higher immunogenicity to induce anti-drug antibodies (ADA). If the immunogenicity of a new candidate can be understood in the nonclinical phase, clinical studies will be safer and the success rate of development improved. Empirically, in vitro immunogenicity assays with human cells have proved to be sufficiently sensitive to nonhuman proteins, but not to human/humanized mAb. To detect the weaker immunogenicity of human-based mAb, a more sensitive biomarker for in vitro assays is needed. The in vitro study here developed a proliferation assay (T H cell assay) using flow cytometry analysis that can detect a slight increase in proliferating T H cells. Samples from 218 donors treated with a low-immunogenic drug (etanercept) were measured to determine a positive threshold level. With this threshold, positive donor percentages among PBMC after treatment with higher-immunogenicity mAb drugs were noted, that is, 39.5% with humanized anti-human A33 antibody (hA33), 27.3% with abciximab, 25.9% with adalimumab, and 14.8% with infliximab. Biotherapeutics with low immunogenicity yielded values of 0% for basiliximab and 3.7% for etanercept. These data showed a good comparability with previously reported incidences of clinical ADA with the evaluated drugs. Calculations based on the data here showed that a T H cell assay with 40 donors could provide statistically significant differences when comparing low- (etanercept) versus highly immunogenic mAb (except for infliximab). Based on the outcomes here, for screening purposes, a practical cutoff point of 3/20 positives with 20 donors was proposed to alert immunogenicity of mAb drug candidates.